Search form

Search form

GlaxoSmithKline expanded a collaboration with NPS Pharmaceuticals to take over development and marketing of ronacaleret. The drug was designed to treat osteoporosis, but GSK will develop it as stem cell transplant therapy. The agreement also grants
NPS development rights to SB-423557 and SB-423562 for autosomal dominant hypocalcemia with hypercalciuria.

Related Summaries

Isis Pharmaceuticals received a milestone payment of $5 million from GlaxoSmithKline after launching
an early-stage trial of its antisense drug ISIS-TTRRx in patients with transthyretin amyloidosis. The compound is part of a collaboration to develop as many as six therapies for rare illnesses.

Abbott Laboratories and GlaxoSmithKline are teaming up to develop a molecular diagnostic test that screens for the MAGE-A3 antigen found in nonsmall-cell lung cancer tumors. The partnership comes as GSK works on the late-stage development of a drug that targets the MAGE-A3 protein.

GlaxoSmithKline announced it is collaborating with a research team from University College London to develop an antibody-based treatment for amyloidosis, a rare disease that causes organ failure. The drug, labeled CPHPC, might be ready for clinical trials within two years, a GSK official said.

Human Genome Sciences will receive a milestone payment of $9 million from GlaxoSmithKline because a late-stage trial for diabetes drug Syncria has begun. The biotech firm has received $24 million in milestone fees to date from its drug-development deal with GSK.

GlaxoSmithKline plans to divide its drug-development teams into more focused groups as it aims to become "more biotech-like" to spur innovation, a company official announced at a conference Monday. The smaller units will concentrate on specific disease areas and will be rewarded "based on successful value creation," GSK drug-discovery head Patrick Vallance said.